跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 14 天前AI 评分25

Sarepta 停止 Elevidys 确认 III 期临床试验入组

Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys

AI 导读

Sarepta 停止 Duchenne 肌营养不良基因治疗药物 Elevidys 的 III 期临床试验入组,该试验旨在确认药物疗效。

正文

Sarep­ta Ther­a­peu­tics won’t en­roll more pa­tients in the Phase 3 tri­al of its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py Ele­v­idys, a test that was meant to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news